RU2016124366A - Ингибиторы протеинкиназы - Google Patents
Ингибиторы протеинкиназы Download PDFInfo
- Publication number
- RU2016124366A RU2016124366A RU2016124366A RU2016124366A RU2016124366A RU 2016124366 A RU2016124366 A RU 2016124366A RU 2016124366 A RU2016124366 A RU 2016124366A RU 2016124366 A RU2016124366 A RU 2016124366A RU 2016124366 A RU2016124366 A RU 2016124366A
- Authority
- RU
- Russia
- Prior art keywords
- inhibitors
- treatment
- compound according
- disease
- compound
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
- A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
- A61K49/10—Organic compounds
- A61K49/101—Organic compounds the carrier being a complex-forming compound able to form MRI-active complexes with paramagnetic metals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/58—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/58—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances
- G01N33/582—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances with fluorescent label
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Organic Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Urology & Nephrology (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- Hematology (AREA)
- Physics & Mathematics (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- Food Science & Technology (AREA)
- General Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Pathology (AREA)
- Cell Biology (AREA)
- Biotechnology (AREA)
- Rheumatology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Optics & Photonics (AREA)
- Radiology & Medical Imaging (AREA)
- Pain & Pain Management (AREA)
- Tropical Medicine & Parasitology (AREA)
- Vascular Medicine (AREA)
- Transplantation (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CA2,834,528 | 2013-11-26 | ||
| CA2834528A CA2834528A1 (en) | 2013-11-26 | 2013-11-26 | Protein kinase inhibitors |
| PCT/CA2014/000848 WO2015077866A1 (en) | 2013-11-26 | 2014-11-26 | Protein kinase inhibitors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| RU2016124366A true RU2016124366A (ru) | 2018-01-09 |
Family
ID=53198134
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2016124366A RU2016124366A (ru) | 2013-11-26 | 2014-11-26 | Ингибиторы протеинкиназы |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US20170158697A1 (enExample) |
| EP (1) | EP3074401A4 (enExample) |
| JP (1) | JP2017503006A (enExample) |
| KR (1) | KR20160089378A (enExample) |
| CN (1) | CN105764906A (enExample) |
| CA (2) | CA2834528A1 (enExample) |
| RU (1) | RU2016124366A (enExample) |
| TW (1) | TW201602112A (enExample) |
| WO (1) | WO2015077866A1 (enExample) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2016187723A1 (en) * | 2015-05-27 | 2016-12-01 | Pharmascience Inc. | Inhibitors of the tec kinase enzyme family |
| CN108794483B (zh) * | 2018-04-27 | 2021-04-23 | 四川大学华西医院 | 一种7-脱氮嘌呤衍生物及其六元环超分子结构 |
| KR20230064355A (ko) | 2021-11-03 | 2023-05-10 | 고려대학교 산학협력단 | N아세틸l트립토판 3,5비스(트리플루오로메틸)벤질 에스테르 화합물을 유효성분으로 포함하는 통증의 예방 또는 치료용 약학적 조성물 |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7863444B2 (en) * | 1997-03-19 | 2011-01-04 | Abbott Laboratories | 4-aminopyrrolopyrimidines as kinase inhibitors |
| CZ2001959A3 (cs) * | 1998-09-18 | 2001-12-12 | Basf Aktiengesellschaft | 4-Aminopyrrolopyrimidiny jako inhibitory kinasy |
| NZ510588A (en) * | 1998-09-18 | 2003-08-29 | Abbott Gmbh & Co | Pyrrolopyrimidines as protein kinase inhibitors |
| US6713474B2 (en) * | 1998-09-18 | 2004-03-30 | Abbott Gmbh & Co. Kg | Pyrrolopyrimidines as therapeutic agents |
| AU2000240570A1 (en) * | 2000-03-29 | 2001-10-08 | Knoll Gesellschaft Mit Beschraenkter Haftung | Pyrrolopyrimidines as tyrosine kinase inhibitors |
| CA2779184A1 (en) * | 2012-05-31 | 2013-11-30 | Pharmascience Inc. | Protein kinase inhibitors |
| BR112014029718A2 (pt) * | 2012-05-31 | 2017-06-27 | Pharmascience Inc | inibidores da proteína quinase |
| CA2813299A1 (en) * | 2013-04-17 | 2014-10-17 | Pharmascience Inc. | Protein kinase inhibitors |
| CA2782774A1 (en) * | 2012-07-06 | 2014-01-06 | Pharmascience Inc. | Protein kinase inhibitors |
-
2013
- 2013-11-26 CA CA2834528A patent/CA2834528A1/en not_active Abandoned
-
2014
- 2014-11-26 EP EP14865858.6A patent/EP3074401A4/en not_active Withdrawn
- 2014-11-26 WO PCT/CA2014/000848 patent/WO2015077866A1/en not_active Ceased
- 2014-11-26 JP JP2016554766A patent/JP2017503006A/ja not_active Withdrawn
- 2014-11-26 TW TW103141063A patent/TW201602112A/zh unknown
- 2014-11-26 US US15/039,127 patent/US20170158697A1/en not_active Abandoned
- 2014-11-26 RU RU2016124366A patent/RU2016124366A/ru unknown
- 2014-11-26 KR KR1020167014057A patent/KR20160089378A/ko not_active Withdrawn
- 2014-11-26 CA CA2929889A patent/CA2929889A1/en not_active Abandoned
- 2014-11-26 CN CN201480064253.3A patent/CN105764906A/zh active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| JP2017503006A (ja) | 2017-01-26 |
| WO2015077866A1 (en) | 2015-06-04 |
| CA2834528A1 (en) | 2015-05-26 |
| CN105764906A (zh) | 2016-07-13 |
| EP3074401A4 (en) | 2017-05-10 |
| CA2929889A1 (en) | 2015-06-04 |
| TW201602112A (zh) | 2016-01-16 |
| EP3074401A1 (en) | 2016-10-05 |
| US20170158697A1 (en) | 2017-06-08 |
| KR20160089378A (ko) | 2016-07-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2521394C2 (ru) | Комбинации, предназначенные для лечения заболеваний, включающих пролиферацию клеток | |
| TWI782906B (zh) | 惡性腫瘤治療用製劑及組合物 | |
| RU2717570C2 (ru) | Синергистические комбинации ауристана | |
| US20130085153A1 (en) | Combination of an iap inhibitor and a taxane for the treatment of a proliferative disease | |
| JP2009512719A5 (enExample) | ||
| RU2016123855A (ru) | Ингибиторы протеинкиназы | |
| JP6754071B2 (ja) | メトホルミン及びジヒドロケルセチンを含む組み合わせ医薬、及びがんの治療のための使用 | |
| JP2009529544A5 (enExample) | ||
| HRP20211920T1 (hr) | Inhibitori za pd-1/pd-l1 | |
| JP2008527038A5 (enExample) | ||
| JP2017528524A5 (enExample) | ||
| MY173494A (en) | Kinase inhibitors | |
| EA201890888A1 (ru) | Новые спиро[3h-индол-3,2'-пирролидин]-2(1h)-оновые соединения и производные в качестве ингибиторов mdm2-p53 | |
| RU2012142550A (ru) | Производные пирролопиразина и их применение в качестве ингибиторов jak и syk | |
| JP2016537367A5 (enExample) | ||
| JP2023537066A5 (enExample) | ||
| RU2014145285A (ru) | Ингибиторы протеинкиназ | |
| US8481503B2 (en) | Combination cancer therapy with an AKT inhibitor and other anticancer agents | |
| KR20200126334A (ko) | 면역항암 보조제 | |
| JP2017503006A5 (enExample) | ||
| RU2016124119A (ru) | Ингибиторы протеинкиназы | |
| RU2016107372A (ru) | Усиление эффекта метотрексата путем комбинированного применения с липофильными статинами | |
| JP2008527039A5 (enExample) | ||
| CA3222752A1 (en) | Combination mcl-1 inhibitors with anti-body drug conjugates | |
| CA3222269A1 (en) | Combination mcl-1 inhibitors with anti-cancer agents |